Sylvant
What Sylvant is used for
Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Sylvant
- Active substance
- siltuximab
- Disease area
- Giant Lymph Node Hyperplasia
- Medicine group
- Immunosuppressants
- ATC code
- L04AC11
- Marketing authorisation holder
- Recordati Netherlands B.V.
- Authorised in the EU since
- 2014
Official information
In the USA
Same active substance: Sylvant
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Sylvant used for?
Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.
What is the active substance in Sylvant?
Sylvant contains siltuximab.
Who makes Sylvant?
The EU marketing authorisation holder is Recordati Netherlands B.V..
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU